Johnson & Johnson's (JNJ) Vision segment targets to deliver mid-to-high single digit growth in the long term, with catalysts like upcoming product launches, contact lens market recovery, and planned increase in capital allocation, RBC Capital Markets said in a Monday note.
Vision is one of the three strategic growth priorities of Johnson & Johnson's MedTech division and is "uniquely positioned" to benefit from the company's digital/AI, manufacturing and regulatory capabilities, RBC said, as it noted the segment's greenfield opportunity in a 2-billion addressable market.
Management expects daily disposable contact lenses and presbyopia-correcting intraocular lenses to continue driving growth, according to the note. Vision generated 2025 sales of $5.5 billion, a 5.3% increase led by the surgical vision and contact lens products, RBC said.
RBC maintained an outperform rating on Johnson & Johnson, with a $255 price target.
Price: 242.20, Change: +1.75, Percent Change: +0.73
Comments